Antibody evolution immunogens
US-2015366961-A1 · Dec 24, 2015 · US
Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
US9682138B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9682138-B2 |
| Application number | US-201514616042-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2015 |
| Priority date | Aug 20, 2007 |
| Publication date | Jun 20, 2017 |
| Grant date | Jun 20, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
First claim
Opening claim text (preview).
We claim: 1. An isolated polypeptide comprising a mutated feline leukemia virus (FeLV) envelope (ENV) polypeptide, wherein the mutated FeLV ENV protein has at least 93% sequence identity to SDQ ID NO:2, 4, or 6, and wherein the mutation is a substitution of arginine (R), aspartic acid (D), or methionine (M) at the amino acid position 527 of SEQ ID NO:2, 4, or 6. 2. A composition comprising the polypeptide of claim 1 , and a pharmaceutically or veterinarily acceptable vehicle, diluent or excipient. 3. The composition of claim 2 , wherein the composition is capable of eliciting an immune response in a host. 4. The isolated polypeptide of claim 1 , wherein the substitution is arginine (R) for glutamic acid (E). 5. The isolated polypeptide of claim 4 , wherein the mutated FeLV ENV polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:2 or 4.
Assignees
Inventors
Classifications
characterised by the type of response, e.g. Th1, Th2 · CPC title
Veterinary vaccine · CPC title
Viral antigens · CPC title
DNA (RNA) vaccination · CPC title
viral genome or elements thereof as genetic vector · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9682138B2 cover?
- The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.
- Who is the assignee on this patent?
- Merial Ltd, Centre Nat Rech Scient, Roussy Inst Gustave, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/21. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).